Innate Pharma (IPHA) Interest Expenses (2019 - 2025)

Innate Pharma (IPHA) has reported Interest Expenses for 7 consecutive years, with -$3.6 million the latest figure, recorded in Q4 2025.

• Quarterly Interest Expenses rose 21.51% year-over-year to -$3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $40966.4 (down 85.6% YoY) and the FY2025 annual result came in at $3.6 million, down 21.51% from the prior year.
• Interest Expenses eased to -$3.6 million in Q4 2025 per IPHA's latest filing, from $3.4 million in the prior quarter.
• Over the last five years, Interest Expenses for IPHA reached as high as $4.7 million in Q2 2024 and fell as low as -$4.5 million in Q4 2021.
• A 5-year average of -$550388.8 and a median of -$1.0 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses slumped 34386.0% — and 2024, when it surged 113.66%.
• Year by year, Interest Expenses stood at -$4.5 million in 2021, then soared by 99.87% to -$6055.1 in 2022, then slumped by 34386.0% to -$2.1 million in 2023, then sank by 116.62% to -$4.5 million in 2024, then advanced by 21.51% to -$3.6 million in 2025.
• According to Business Quant data, Interest Expenses over the past three periods registered -$3.6 million, $3.4 million, and -$4.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.